Illumina, Inc. (ILMN) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Illumina (ILMN) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Illumina is the dominant maker of DNA sequencing systems, and it sells the reagents and consumables those machines need to run, so a large installed base produces a recurring, razor-and-blades revenue stream. After spinning off GRAIL the company has refocused on its core sequencing and emerging multiomics franchise. As of 16 October 2026 the stock closed at $260.52, up about 94% in 2026, for a market value near $39 billion. The single biggest risk is that the sequencing market is growing slowly while newer, cheaper rivals chip at Illumina's share.
ILMN stock price
As of 2026-11-16, Illumina, Inc. (ILMN) last closed at $198.00, up 64.9% over the past year. Over the past 52 weeks it has traded between $114.44 and $293.69.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Illumina, Inc.'s investor relations page. Walnut is informational, not investment advice.
ILMN key stats
At $198.00 on November 16, 2026, Illumina, Inc. (ILMN) has a market cap of $29.9B and a P/E of 34.1 on trailing earnings (32.0 on forward earnings).
- Market cap
- $29.9B
- P/E (trailing)
- 34.1
- P/E (forward)
- 32.0
- EPS (trailing 12 months)
- $5.81
- Price to book
- 9.6
- Beta
- 1.45
Market cap, P/E and yield are measured at the $198.00 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Illumina, Inc. (ILMN)?
The last two weeks for Illumina, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ILMN closed at $198.00 on November 16, 2026, down 10.3% over the past five trading days (from $220.78).
Illumina, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Illumina, Inc. (ILMN) latest quarter
Illumina reported revenue of $1.1 billion for Q3 fiscal 2026, up 4% from a year earlier (Illumina, Oct 29, 2026).
Source: Illumina Q3 fiscal 2026 results, Oct 29, 2026. Full earnings breakdown
What does Illumina, Inc. (ILMN) do?
Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Its business follows a razor-and-blades model: instruments such as the high-throughput NovaSeq X, the NextSeq, and the benchtop MiSeq seed an installed base, and the bulk of revenue then comes from recurring sequencing consumables (reagents and flow cells), which historically make up the majority of sales. The company is also pushing into multiomics, proteomics, and clinical diagnostics to expand what its platforms can measure. Illumina is headquartered in San Diego, was founded in 1998, and is led by CEO Jacob Thaysen.
Illumina's recent history was dominated by its acquisition of cancer-screening company GRAIL and the regulatory fight that followed. Antitrust authorities in the US and Europe challenged the deal, the European Commission ordered a divestiture in 2023, and Illumina distributed about 85.5% of GRAIL to its shareholders in June 2024, separating the two companies. In September 2024 the European Court of Justice annulled the Commission's jurisdiction over the original review, and Illumina avoided a 432 million euro fine. With GRAIL gone, management has refocused the company on its core sequencing platforms, consumables growth, multiomics, and operating-margin recovery.
In 2026 the story has been one of steady beats and a sharply higher share price. Revenue reached about $1.16 billion in the second quarter of 2026, with adjusted EPS of $1.31 against a $1.23 consensus, the fourth consecutive quarter ahead of estimates. In October 2026 Illumina launched BioInsight, its first unified software environment for genomic and multiomic analysis, alongside AI tools such as its SpliceAI2 model, and announced a $1 billion commercial paper program. An FDA recall listing also appeared for an earlier server correction on the NovaSeq 6000Dx clinical instrument.
What's driving Illumina, Inc. (ILMN)?
1. Installed base and the consumables annuity.
Illumina's core advantage is the large base of sequencers already in labs, which pulls through recurring reagent and flow-cell purchases. Sequencing consumables revenue was about $755 million in the fourth quarter of 2025, up 8% year over year and roughly 11% excluding China. As long as customers keep running these machines, consumables provide a relatively sticky, high-visibility revenue stream.
2. The NovaSeq X transition.
The high-throughput NovaSeq X drives lower cost per genome and higher consumables volume as it replaces older systems. Illumina reported the installed base reaching roughly 890 instruments by the end of 2025, with the research transition nearly complete and clinical conversion past two-thirds. Each placement seeds future consumables demand, so the pace of conversion matters to the growth story.
3. Multiomics and clinical diagnostics.
Beyond DNA sequencing, Illumina is expanding into proteomics, single-cell, and spatial methods, and is leaning into clinical applications such as comprehensive genomic profiling in oncology and whole-genome sequencing in genetic disease. Clinical consumables excluding China grew about 20% in the fourth quarter of 2025, a faster-growing mix the company is trying to enlarge.
4. Margin recovery.
After the GRAIL distraction and a cost-reduction program, Illumina is targeting improved profitability. For fiscal 2026 it guided to a non-GAAP operating margin in roughly the 23.3% to 23.5% range, and its trailing twelve month GAAP operating margin stood near 21% by mid 2026, with gross margin near 68% and net margin near 18%. Continued margin expansion is a key part of how the company frames its earnings recovery.
5. Software and AI on top of the sequencer.
Illumina is trying to capture more of the analysis that happens after sequencing. In October 2026 it launched the BioInsight Platform, described as its first unified software environment for genomic and multiomic research, and expanded AI tools including the SpliceAI2 model for interpreting genetic variants. Software revenue is small next to consumables, but it ties customers more closely to the Illumina workflow.
What are the risks to Illumina, Inc. (ILMN)?
Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk. Valuation is now a larger part of the risk: at about 48 times trailing earnings and roughly 8.8 times sales after a 94% gain in 2026, the stock trades above the average analyst target of about $241, and the consensus for the third quarter calls for EPS of about $1.36 on revenue of about $1.15 billion, roughly 1% growth. A recall listing for the NovaSeq 6000Dx server correction is a reminder that clinical instruments carry regulatory exposure.
What is the Illumina, Inc. (ILMN) forecast?
20 analysts publish price targets on ILMN, averaging $261.45 as of November 2026, or +32.0% against the $198.00 share price on November 16, 2026. The published targets run from $165.00 to $365.00, a wide spread, and the ratings split 10 buy, 7 hold, 4 sell. Over the last six months there have been 10 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full ILMN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is ILMN a buy or a sell?
We give no verdict on Illumina, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Installed base and the consumables annuity. Illumina's core advantage is the large base of sequencers already in labs, which pulls through recurring reagent and flow-cell purchases. The most optimistic published target, $365.00, assumes this works close to its best case.
The case against. Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The most pessimistic target, $165.00, is roughly what ILMN is worth if this bites instead.
Read the full bull and bear case on ILMN, including what would have to change to break either one. Walnut is not an investment adviser.
Has Illumina, Inc. (ILMN) split its stock?
Yes. Illumina, Inc. (ILMN) has had one share split in the last 10 years:
- 1028:1000 on June 25, 2024, so every share held became 1.028 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of ILMN the day before the 1028:1000 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Illumina, Inc. (ILMN) valued?
Market cap, P/E and dividend yield at today's price are in the ILMN key stats above. The business figures below come from Illumina, Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$4.49 billion; Q2 2026 revenue ~$1.16 billion, up ~9% year over year
- 2026 revenue consensus: ~$4.62 billion (~11% growth); 2027 consensus ~$4.92 billion
- Margins (TTM): Gross ~68%, operating ~21%, net ~18%
- Dividend: None
- Cash and debt: ~$1.17 billion cash, ~$2.53 billion debt; ~$0.8 billion TTM free cash flow
As of October 2026: Illumina's multiple has expanded far faster than its earnings: the shares are up about 94% year to date and 172% over a year, while consensus calls for 2026 revenue growth near 11% and EPS of about $5.36. At roughly 43 times forward earnings and 36 times EV/EBITDA, the price assumes growth and margin expansion continue well beyond 2026, and the stock sits above the $241 average analyst target even as individual targets, such as JPMorgan's move to $320, have risen.
Which ETFs hold Illumina, Inc. (ILMN)?
If you want ILMN exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.
| ETF | Name | % in ILMN | Expense ratio | |
|---|---|---|---|---|
| MDY | State Street SPDR S&P MidCap 400 ETF Trust | 0.91% | 0.23% | |
| ARKG | ARK Genomic Revolution ETF | 4.5% | 0.75% | |
| RSP | Invesco S&P 500 Equal Weight ETF | 0.27% | 0.20% | |
| ROBO | Robo Global Robotics and Automation Index ETF | 1.73% | 0.95% | |
| VB | Vanguard Morningstar Small-Cap ETF | 0.38% | 0.03% | |
| BBH | VanEck Biotech ETF | 4.0% | 0.35% | |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 4.39% | 0.55% | |
| IBB | iShares Biotechnology ETF | 2.89% | 0.44% | |
| ROBT | First Trust Nasdaq Artificial Intelligence and Robotics ETF | 2.00% | 0.65% | |
| FMDE | Fidelity Enhanced Mid Cap Core ETF | 0.9% | 0.23% | |
| IVOO | Vanguard S&P Mid-Cap 400 Index Fund ETF Shares | 0.9% | 0.07% |
Who competes with Illumina, Inc. (ILMN)?
Diversified life-science tools
Thermo Fisher Scientific competes in sequencing through its Ion Torrent platform and overlaps broadly with Illumina across reagents, instruments, and genomics workflows, with far greater scale and product breadth across the life-science tools market.
Long-read sequencing
Pacific Biosciences (PacBio) and Oxford Nanopore Technologies focus on long-read sequencing, a niche where their technologies can read longer DNA fragments than Illumina's short-read systems. They compete for research budgets and increasingly for clinical applications.
New short-read challengers
Ultima Genomics and Element Biosciences are venture-backed entrants attacking Illumina on cost per genome. Ultima markets bulk whole-genome sequencing near $80 a genome, and Element's AVITI undercuts benchtop running costs, pressuring Illumina's pricing and incremental placements.
China and global
MGI, affiliated with BGI, dominates the Chinese sequencing market and is expanding internationally. After Illumina was effectively shut out of China, MGI and BGI hold the majority of new placements there, though sanctions have limited their access to North American and European markets.
What stocks are similar to Illumina, Inc. (ILMN)?
Other names that sit close to ILMN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Illumina, Inc. (ILMN)
There are three common ways to get ILMN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (MDY, ARKG, RSP), which spreads the position across many companies. Or build it into a focused thematic portfolio, so ILMN sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where ILMN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Illumina, Inc. (ILMN)
Illumina (ILMN) today is a focused sequencing company whose main driver is the consumables pulled through its growing NovaSeq X installed base, which reached roughly 890 instruments by the end of 2025, against full-year 2025 revenue of about $4.34 billion and trailing twelve month revenue of about $4.49 billion by mid 2026. The shares have nearly doubled in 2026 and trade near 48 times trailing and 43 times forward earnings, above the roughly $241 average analyst target, so much of the recovery is already in the price. If you believe Illumina keeps its platform lead and consumables annuity intact while operating margins recover, the question becomes sizing and overlap with other healthcare or genomics positions you hold, not timing. The risk is that competition from lower-cost sequencers, soft research funding, and lost China sales keep top-line growth in the single digits, or that the multiple compresses if results merely meet expectations. Third quarter results are due on 29 October 2026.
More on Illumina, Inc. (ILMN)
Whether ILMN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ILMN a buy or a sell?, and where the stock could go from here in the ILMN stock forecast.
For income investors, whether ILMN pays a dividend and how the payout looks is covered in does ILMN pay a dividend? And to weigh ILMN against a peer, read the full side-by-side comparisons: ILMN vs TMO and ILMN vs DNA.
Wondering how ILMN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Illumina, Inc.
Ask Walnut's AI anything about ILMN and see how it fits what you own.
FAQ
What does Illumina do?
+
Illumina makes next-generation DNA sequencing systems and the consumables that run on them, used in genomics research, clinical diagnostics, and applied markets. It follows a razor-and-blades model: instruments such as the NovaSeq X, NextSeq, and MiSeq seed an installed base, and most revenue comes from recurring reagents and flow cells. The company is also expanding into multiomics.
What is Illumina's (ILMN) ticker symbol?
+
ILMN, listed on Nasdaq. Officially Illumina, Inc., headquartered in San Diego, California, and founded in 1998. It is a constituent of the S&P 500 and Nasdaq-100 and trades during US market hours at every major US brokerage, where you can buy whole or fractional shares.
What happened with Illumina and GRAIL?
+
Illumina acquired cancer-screening company GRAIL, but antitrust regulators in the US and Europe challenged the deal. The European Commission ordered a divestiture, and Illumina distributed about 85.5% of GRAIL to shareholders in June 2024. In September 2024 the European Court of Justice annulled the Commission's jurisdiction, and Illumina avoided a 432 million euro fine.
Does Illumina (ILMN) pay a dividend?
+
No. As of October 2026 Illumina does not pay a dividend. The company directs cash toward research and development, its platform transition, and operations rather than a regular payout, so total return depends on the share price. Dividend policy can change, so verify the current status before relying on it.
How does Illumina make money?
+
Most of Illumina's revenue is recurring sequencing consumables, the reagents and flow cells customers buy to run their machines, which historically make up the majority of sales. Instruments such as the NovaSeq X drive placements that seed future consumables demand. Services, software, and emerging multiomics products round out the mix. Full-year 2025 revenue was about $4.34 billion.
Who are Illumina's main competitors?
+
Thermo Fisher Scientific competes through Ion Torrent. PacBio and Oxford Nanopore lead long-read sequencing. Ultima Genomics and Element Biosciences are newer challengers attacking cost per genome, with Ultima near $80 a genome and Element's AVITI undercutting benchtop economics. MGI, affiliated with BGI, dominates the Chinese market and is expanding abroad.
How exposed is Illumina to China?
+
Much less than before. After Illumina was effectively shut out of the Chinese market, management said sales outside China were about 97% of revenue in 2025, leaving China at roughly 3%. Domestic players BGI and MGI dominate Chinese sequencing. The lost China business is a headwind already reflected in recent results; verify the latest disclosures.
Is ILMN a good stock to buy right now?
+
Descriptive, not a recommendation. The bull case is a dominant sequencing platform, a sticky consumables annuity, the NovaSeq X transition, multiomics expansion, and recovering margins. The bear case is slow market growth, intensifying low-cost competition, soft research funding, lost China sales, and a high valuation near 48 times trailing earnings after the stock nearly doubled in 2026. Whether it fits depends on your goals, time horizon, and risk tolerance. Walnut is informational, not investment advice.
How did Illumina do in its latest quarter?
+
In the second quarter of 2026, Illumina reported revenue of about $1.16 billion and GAAP net income of about $207 million, with adjusted EPS of $1.31 against a consensus of $1.23. That was the fourth straight quarter ahead of EPS estimates, following beats of $1.34 vs $1.17, $1.35 vs $1.23 and $1.15 vs $1.05. Third quarter results are scheduled for 29 October 2026, with consensus near $1.36 of EPS on about $1.15 billion of revenue.
How has ILMN stock performed in 2026?
+
ILMN closed at $260.52 on 16 October 2026, up about 94% year to date and roughly 172% over twelve months, after trading as low as $94 and as high as about $309 over the past 52 weeks. It gained about 35% over the last three months and about 9% over the last month. The move has lifted the market value to around $39 billion and the trailing P/E to roughly 48. Walnut is not an investment adviser, and past performance is not a guide to future returns.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Illumina, Inc.'s investor relations page or your broker before making investment decisions.